C
Chunfu Wang
Researcher at Bristol-Myers Squibb
Publications - 36
Citations - 5005
Chunfu Wang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: NS5A & Hepatitis C virus. The author has an hindex of 25, co-authored 31 publications receiving 4891 citations. Previous affiliations of Chunfu Wang include University of Texas System & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Journal ArticleDOI
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease
TL;DR: The NS3/4A protease represents a dual therapeutic target, the inhibition of which may both block viral replication and restore IRF-3 control of HCV infection.
Journal ArticleDOI
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.
Eileen Foy,Kui Li,Rhea Sumpter,Yueh Ming Loo,Cynthia L. Johnson,Chunfu Wang,Penny Mar Fish,Mitsutoshi Yoneyama,Takashi Fujita,Stanley M. Lemon,Michael Gale +10 more
TL;DR: It is demonstrated that disruption of retinoic acid-inducible gene I (RIG-I) signaling by the viral NS3/4A protease contributes to the ability of HCV to control innate antiviral defenses.
Journal ArticleDOI
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation
TL;DR: It is reported that HCV RNA replication and assembly of the viral replication complex require geranylgeranylation of one or more host proteins, and inhibition of its geranylgersanylation affords a therapeutic strategy for treatment of HCV infection.
Journal ArticleDOI
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.
Chunfu Wang,Michael Gale,Brian C. Keller,Hua Huang,Michael S. Brown,Joseph L. Goldstein,Jin Ye +6 more
TL;DR: The current data indicate that geranylgeranylated FBL2 binds to NS5A in a reaction crucial for HCV RNA replication.